drugset

drugset / Trial / NCT02242071

Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

NCT02242071 ↗

Phase 1 Withdrawn Neurogen Brain and Spine Institute

NaSingle-groupOpen-labelTreatment

Summary

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

Timeline

Start: 2008-12
Primary completion: 2015-03
Completion: 2016-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Stem Cell	Cell therapy	—	Intrathecal

Indications